Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979773 | 0.94 | ESR1 (0.32) | HPDMAPTLMNAKMT2AMAPK1 | |
| SCHEMBL1194496 | 0.92 | HTT (0.34) | HPDMAPTLMNAKMT2AMAPK1 | |
| SCHEMBL12981016 | 0.84 | SMN1; SMN2 (0.35) | HPDMAPTLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL12980888 | 0.81 | ADRB2 (0.37) | HPDADRB2HTT | |
| SCHEMBL1186945 | 0.78 | HTT (0.38) | HPDMAPTLMNAKMT2AMAPK1 | |
| SCHEMBL2582039 | 0.77 | ADRB2 (0.38) | HPDMAPTLMNAKMT2AMAPK1 | |
| SCHEMBL1185442 | 0.77 | ADRB2 (0.38) | HPDMAPTLMNAKMT2AMAPK1 | |
| Cadaverine Tartrate SCHEMBL12981095 | 0.76 | GRM8 (0.39) | — | |
| Hydrochloric Acid SCHEMBL1185967 | 0.76 | ADRB2 (0.40) | HPDMAPTLMNAKMT2AMAPK1 | |
| SCHEMBL12980184 | 0.74 | APP (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518056-B1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8846660-B2 | Seven-membered ring compound and pharmaceutical use therefor | DAIICHI SANKYO COMPANY, LTD. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2518056-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | CMA1, CPA3, TMPRSS15 | HPD 1664/4885MAPT 3457/4885LMNA 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.